In contrast, our work shows that HER2-positive breast cancer cells gain the ability to become resistant to lapatinib through the dramatic remodelling of the chromatin, transcriptome and the proteome (Fig. 5b, c). The gene discussed is ERBB2; the disease is breast carcinoma.